Category Archives: Public Policy

Latest From Public Policy

BIO Deputy General Counsel Remarks on Revised Eligibility Guidance

Supreme Court

Hans Sauer, BIO’s Deputy General Counsel for Intellectual Property recently spoke at the U.S. Patent and Trademark Office’s public forum on patent-eligible subject matter. The forum was a chance for the Office to receive public feedback regarding the most recently revised Eligibility Guidance for determining subject matter under 35 U.S.C. 1010. Biotechnology advocates are concerned that PTO examiners have interpreted recent decisions by the U.S. Supreme Court, including those in Alice Corp, Myriad, and Mayo Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , , , , , , ,

Sens. Alexander and Burr Release “Innovation for Healthier Americans” Report


Today, Senate HELP Committee Chairman Lamar Alexander (R-Tenn.) and committee member Richard Burr (R-N.C.) released a report on the challenges of ‘getting safe treatments, devices and cures to patients more quickly and effectively.’ Specifically, the report looks at what is and is not working at the Food and Drug Administration and the National Institutes of Health. The report kicks off a major initiative by the Committee to examine challenges with drug and medical device development Read More >

Business and Investments, Health, Public Policy  |  Leave a comment  |  Email This Post

Chairman Upton and Rep. DeGette Op-Ed: Can We Find Cures for 7,000 Diseases?

21st Century Cures Act

In a op-ed, Energy & Commerce Committee Chairman Fred Upton (R-MI) and Representative Diana DeGette (D-CO) provide highlights of policies that they intend to propose to help get more cures and treatments for the more than 7,000 diseases for which only 500 have cures and treatments. Chairman Upton and Rep. DeGette launched the 21st Century Cures Initiative to identify areas of reform to help ‘close the gap between the science of medicine and the Read More >

Business and Investments, Events, Health, Public Policy  |  Leave a comment  |  Email This Post
Tags: , , , , , , ,

USPTO Issues New Myriad Guidance


On Tuesday, December 16 the United States Patent and Trademark Office issued a revised guidance on subject matter eligibility under § 101 in light of recent Supreme Court Decisions in Alice v. CLS Bank, Mayo, and Myriad. These new guidelines are a response to extensive feedback provided from industry leaders and inventors over the last several months. (BIO provided both initial and supplemental comments on the Office’s March Subject Matter Eligibility Guidance). Public comments on the Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , , ,

Patently Biotech’s Top Articles of 2014


It’s been a whirlwind year for IP. From international trade negotiations, to revised PTO guidelines and dropping patent case stats, intellectual property is on the brain and in the news. Here are Patently Biotech’s top blog posts of 2014: TPP and IP: The Economic Benefits of a Pacific Trade Agreement Should the USPTO allow the patenting of living organisms? Gene Patent Questions Remain: USPTO Issues Examiner Guidelines Stopped at the Threshold: A New Study Reports Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , ,